Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.
DVA
STRONG BUYREMOVEDaVita Inc. · Healthcare · United States · $13.9B · Avg Vol: $190M/d
DaVita is a high-quality business, but it operates in a highly regulated US-centric healthcare niche that lacks a compelling connection to the identified macro inflections. It is a 'fine' company, but lacks the asymmetric geopolitical or tech tailwinds required for a 15-position portfolio.
COMPANY DESCRIPTION
DaVita Inc. is a leading global provider of kidney dialysis services, operating an extensive network of outpatient dialysis centers across the United States and internationally. The company benefits from its significant scale, robust clinical outcomes, and integrated care model designed to improve patient health and quality of life. DaVita's competitive moat is reinforced by its strong brand recognition, established relationships within the healthcare system, and a deeply embedded role in managing chronic kidney disease.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11.6B | 12.1B | 12.8B | 13.6B | 5.5% | 13.8B | 14.1B | 14.6B | 3.5% |
| EPS | 6.03 | 7.62 | 11.02 | 10.06 | 18.6% | 10.33 | 13.84 | 16.07 | 26.4% |
| Shares | 90.4M | 88.8M | 80.5M | 68.5M | -24.2% | 64.2M | — | — | — |
| Debt | 11.8B | 11.1B | 12.1B | 12.9B | 2.9% | 13.2B | — | — | — |
| Equity | 712.3M | 1.1B | 121.1M | -651.1M | -58.8% | — | — | — | — |
| Op CF | 1.6B | 2.1B | 2.0B | 1.9B | 6.4% | 2.0B | — | — | — |
| Inv CF | -630.3M | -771.8M | -771.4M | -654.9M | — | — | — | — | — |
| Fin CF | -1.1B | -1.2B | -816.9M | -1.4B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DVA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| DVA | DaVita Inc.(you) | $13.9B | 96 | STRONG BUY |
| THC | Tenet Healthcare Corporation | $16.3B | 94 | STRONG BUY |
| EHC | Encompass Health Corporation | $10.1B | 87 | STRONG BUY |
| UHS | Universal Health Services, Inc. | $8.8B | 88 | STRONG BUY |
| CHE | Chemed Corporation | $6.1B | 89 | STRONG BUY |
| PACS | PACS Group, Inc. | $6.6B | 82 | STRONG BUY |
| NHC | National HealthCare Corporation | $3.2B | 91 | STRONG BUY |
| GRDN | Guardian Pharmacy Services, Inc. | $2.7B | 91 | STRONG BUY |
| MD | Pediatrix Medical Group, Inc. | $2.0B | 97 | STRONG BUY |
| CON | Concentra Group Holdings Parent, Inc. | $3.9B | 82 | STRONG BUY |
Peer medians: ROE -21.7% · P/E 27.1x · Gross margin 44.5%